The research report categorizes the Europe radioimmunoassay (RIA) market by type into two segments: analyzers and reagents & kits. Based on application, the market has been segmented into research and clinical diagnostics, providing exhaustive value analysis for 2014 as well as forecast up to 2020. The end users include hospitals, clinical diagnostics labs, academics, pharmaceutical industry and CRO, & others. The market is comprehensively analyzed at a granular level based on geography, into Germany, France, U.K., Italy, Spain, and Rest of the Europe to provide in-depth information.
The technique of radioimmunoassay (RIA) is advanced and sensitive enough to find small molecules in the blood, and is therefore used for research purposes and diagnosis of diseases, such as cancer. This technique is also implemented by organizations and research labs for research purposes using serum from animals or humans. The new range of immunoassay kits and analyzers provide remedies for autoimmune diseases, such as diabetes. These are widely used in the process of drug discovery and screening in blood banks.
Radioimmunoassay (RIA) is one of the pivotal and traditional methods used for the testing of endocrinological disorders. RIA also has prominent usage in the field of neurodegenerative disorders. In spite of the high precision, robust nature, and impeccable sensitivity, the global radioimmunoassay (RIA) market has been witnessing a slow growth in terms of market values and kit volumes. This can be attributed to the paradigm shift in the adoption of alternatives, such as, ELISA, chemiluminescence assay, immunofluorescence assay, & other non-radio techniques and lack of automation.
In Europe, many clinical laboratories are taking measures to remove RIA tests off their shelf; ELISA has been instrumental in taking over the RIA tests. European Greens has been instrumental in maintaining environmental responsibility across geographies. The utilization of radioactive substances in RIA procedures poses a threat to environment and human health. Thus, the political scenario has negatively impacted the use of RIA tests in Europe due to the conscious effort from the European Greens. In spite of the above-mentioned dynamics, Europe captures a major market share in RIA globally. Majority of the RIA manufacturers are based out of Europe, thus claiming a strong footprint in Europe.
In-depth market share analysis, by revenue, of the top companies is also included in the report. These numbers are arrived at, based on key facts, annual financial information from SEC filings, annual reports and interviews with industry experts, key opinion leaders such as CEOs, directors, and marketing executives. In addition, the report also profiled key players of the market on various parameters such as business overview, financial overview, product portfolio, business strategies and recent developments of the respective company. The major players in the radioimmunoassay are IBL International (A Tecan Company) (Germany), Cisbio (France), DiaSorin S.p.A. (Italy), Izotop (Hungary), Berthold Technologies GmbH & Co. KG (Germany), and Stratec Biomedical AG (Germany), Euro Diagnostica AB (Sweden), DIAsource ImmunoAssays SA (Belgium), PerkinElmer, Inc. (U.S.), MP Biomedicals, LLC (U.S.), DRG International, Inc. (U.S.), & Beckman Coulter, Inc. (U.S.).
Our reports have been used by over 10K customers, including:
The global in-vitro diagnostics market is expected to reach US$ 90,656.80 million by 2027 from US$ 63,746.63 million in 2019. The market is estimated to grow at a CAGR of 4.5% from 2020 to 2027. The in-vitro diagnostics market has accounted for a significant market share in the global healthcare industry during the COVID-19 pandemic.The...
India In-vitro diagnostics market estimated to be valued at USD USD 1255.18 million in 2020 and is expected to reach approximately USD 1990.99 million in 2026, registering a CAGR of nearly 7.10% during the forecast period. In the context of COVID-19, government organizations in various countries, research institutes, and many global...
The United States In Vitro Diagnostics (IVD) market is predicted to reach nearly US$ 37 Billion by 2026. In-vitro Diagnostics (IVD) serves a key role in the healthcare value chain by significantly influencing the quality of health outcomes, patient treatment, care and downstream resource requirements. With an aging population, technological...
The global in-vitro diagnostics market size is projected to reach USD 96.0 billion by 2025 from USD 84.5 billion in 2020, at a CAGR of 2.6% during the forecast period. Market growth is attributed to the rising per capita income in developed and developing countries and technological advancements introduced in the in-vitro diagnostic devices. By...
The global cell isolation market size is projected to reach USD 15.0 billion by 2025 from USD 6.9billion in 2020, at a CAGR of 16.8% during the forecast period. Market growth is driven by factors The growing investments in personalized medicine can primarily be attributed to the growing demand for advanced treatments with minimal side-effects...
198 pages •
By Asia Market Information & Development Company
• Sep 2020
China’s demand for In Vitro Diagnostics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...
94 pages •
By Asia Market Information & Development Company
• Sep 2020
This study focuses on China’s In Vitro Diagnostics industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s...
Global In Vitro Diagnostic Market to Reach $113.86 Billion by 2030 Market Report Coverage - In Vitro Diagnostic Market Segmentation • Product – Instruments, Consumables, and Software • Test Type – Immunoassay, Clinical Chemistry, Whole Blood Glucose Monitoring, Molecular Diagnostics,...
Summary Proteomics International Laboratories Ltd (Proteomics) operates as a medical technology company that discovers new biopharmaceutical drugs.The company harnesses its proprietary proteomics-based technology platform to work in three integrated areas; diagnostics, analytical services and drug discovery. Proteomics...
In Vitro Diagnostics
Medical Devices Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.